Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CORONA: Rosuvastatin in Heart Failure
NCT00206310Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2003
- Primary completion
- Jul 2007
- Modality
- Orthosteric Ligands
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial comparing Rosuvastatin with Placebo (2 arms). Primary endpoint: Composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. Started Sep 2003; status: completed.
02
Drugs
rosuvastatin
Beyond the preview
Go deeper on NCT00206310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00206310.